Clinical trial
TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With…
NCT00258557 · Tibotec Pharmaceuticals, Ireland, Industry · Completed
Key facts
| NCT number | NCT00258557 |
|---|---|
| Title | TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications. |
| Official title | Phase III Randomized, Controlled, Open-label Trial to Investigate the Antiviral Activity, Tolerability and Safety of TMC114/r in Treatment- Naive HIV-1 Infected Patients. |
| Lead sponsor | Tibotec Pharmaceuticals, Ireland, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV |
| Intervention type | Drug |
| Interventions | LPV/RTV, TMC-114/RTV |
| Enrollment | 692 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | May 1, 2012 |
| First posted | Nov 24, 2005 |
| Last update posted | Jun 26, 2013 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, Chile, Costa Rica, Denmark, France, Germany, Greece, Guatemala and 13 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: